BAY 1905254 is good to go
HOLON, Israel—The U.S. Food and Drug Administration has given the green light to Bayer AG’s IND application for BAY 1905254. The first-in-class immuno-oncology therapeutic antibody targets the ILDR2 protein in advanced solid tumors, an immune checkpoint discovered by Compugen. In keeping with a collaboration and license agreement between Compugen and Bayer, the two companies jointly worked on preclinical research for BAY 1905254, and Bayer is now responsible for its clinical development.
Dr. Anat Cohen-Dayag, president and CEO of Compugen, said that, “Bayer has been an excellent partner for us, and we are delighted to see their commitment to advance this promising program. Together with COM701, our anti-PVRIG therapeutic antibody, there are now two new first-in-class programs, discovered by our unique computational platform, in the clinic.”